Try our Advanced Search for more refined results
Life Sciences
-
April 21, 2026
Biotech Co. Investors Clash Over 'Self-Dealing' Claim
Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.
-
April 21, 2026
Congress Rallies More For Bills On Copyrights Than Patents
There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.
-
April 21, 2026
Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge
A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.
-
April 21, 2026
Pfizer, Dexcel Take Two Patents Off Table For Bench Trial
Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.
-
April 21, 2026
Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case
The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.
-
April 21, 2026
Pot Management Co. Says It's Allowed Biz Tax Deduction
A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.
-
April 21, 2026
Squires Stands By Ending Skincare IPR Over ITC Overlap
U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.
-
April 21, 2026
Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit
A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.
-
April 21, 2026
Purdue Pharma Sentencing Punted For In-Person Attendance
A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.
-
April 21, 2026
Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit
Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.
-
April 21, 2026
Philly Zantac Judge Again Declines To Recuse From Cases
A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.
-
April 20, 2026
Armistice Head Testifies He Accidentally Deleted Texts
Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.
-
April 20, 2026
Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases
A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.
-
April 20, 2026
'Kind Of Lawyering We Don't Like': Judge Rips Quinn Emanuel
Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.
-
April 20, 2026
Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told
Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.
-
April 20, 2026
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.
-
April 20, 2026
SEC Says Adviser Traded On Firm Clients' Confidential Info
The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.
-
April 20, 2026
PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation
Georgia residents accusing carpet and chemicals manufacturers of contaminating their properties with forever chemicals urged a state court to reject Shaw Industries' bid to appeal the recent nondismissal of their claims, arguing the request is the carpet company's latest "attempt to derail this litigation."
-
April 20, 2026
PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case
A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.
-
April 20, 2026
She Has A Point: Fish & Richardson's Nitika Gupta Fiorella
Fish & Richardson PC principal Nitika Gupta Fiorella is "a no-stone-unturned, always super prepared" lawyer who "epitomizes professionalism and respect," according to Finnegan Henderson Farabow Garrett & Dunner LLP partner Cora Holt.
-
April 20, 2026
Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told
Counsel for the family of a man who died of an opioid overdose at age 26 told a Philadelphia jury that his doctors were responsible for pushing treatment plans that allowed him to develop an opioid addiction, leading to his untimely death, pointing to both physicians being paid speakers for the pharmaceutical companies whose medications they prescribed.
-
April 20, 2026
Justices Mull Limits On Federal Review Of State Cases
The U.S. Supreme Court on Monday wrestled with the potential impact of reining in — or even scrapping altogether — a 100-year-old doctrine that curbs litigants' ability to go to federal court to try to overturn a state court loss.
-
April 20, 2026
House Panel Probes Reports Of Missing, Killed Scientists
Two Republican U.S. congressmen announced a probe Monday into reports of about a dozen scientists or government employees with ties to American nuclear and space programs who were killed or reported missing, penning letters seeking information from NASA, the Department of Energy, the FBI and the Defense Department.
-
April 20, 2026
GSK, Moderna Both Ordered To Provide More Info In Vax Fight
A special master overseeing discovery disputes in GlaxoSmithKline's infringement suits over Moderna's COVID-19 and related respiratory syncytial virus vaccines ordered both companies to furnish information to each other, including financial data and licenses, according to an opinion unsealed Monday.
-
April 20, 2026
Trump Orders Agencies To Fast-Track Psychedelic Therapies
President Donald Trump on Saturday announced that his administration would instruct federal agencies to accelerate investigations into new therapies derived from psychedelic drugs and streamline patients' access to the treatments.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
At The Fed. Circ., Means-Plus-Function Is Not Quite Dead
Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.
-
E-Discovery Quarterly: Recent Rulings On ESI Control
Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.
-
Opinion
USPTO Should Let Inventors Valuate Patents In Prosecution
By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.
-
2 Discovery Rulings Break With Heppner On AI Privilege Issue
While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.
-
Series
Isshin-Ryu Karate Makes Me A Better Lawyer
My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.
-
Microplastics On Water Contaminant List Could Spur Claims
The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.
-
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.
-
Peptide Policy Is Shifting Toward Sanctioned Compounding
The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.
-
Keys To Building Defensible Psychedelic Therapy Programs
Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.
-
Opinion
State Bars Need To Get Specific About AI Confidentiality
Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.
-
Series
Alpine Skiing Makes Me A Better Lawyer
Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.
-
FDA Guidance May Move Goalposts For Form 483 Responses
New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.
-
2 Strands Of Patent Law In High Court's 'Skinny Label' Case
Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.
-
Why MDLs Slow Down — And How To Speed Them Up
Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.
-
A Check-Up On HHS' Push To Implement AI Infrastructure
The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.